1
|
Candelaria M, Cervera-Ceballos E, Meneses-García A, Avilés-Salas A, Lome-Maldonado C, Zárate-Osorno A, Ortiz-Hidalgo C, Rodríguez-Moguel L, Quiñónez-Urrego EE, Ramos-Salazar P, Romero-Guadarrama MB, Lara-Torres C, Ramírez-Aceves R, López-Navarro O, Rivas-Vera S, Díaz-Meneses IE, Estrada-Lobato E, Cervera-Ceballos J, Rojas-Marín CE, Hernández-Rodriguez JM, Pérez-López B, Gómez-Almaguer D, Altamirano-Ley J, Baz P, Valero-Saldaña LM, Navarrete-Herrera JR, Torres-Salgado FG, Solano-Murillo P, Nambo-Lucio MDJ, Rivas-Llamas R, Aquino-Salgado JL, Avila-Arreguín EV, Cortês-Esteban P, Chongo-Alfaro ML, Pérez-Ramírez ODJ, Toledano-Cuevas DV, Lobato-Mendizábal E, Martínez-Ramírez MA, Morales-Maravilla A, Sosa-Camas RE, Agreda-Vásquez GP, Camacho-Hernández A, Aguayo-González A, Espinoza-Zamora JR, Sánchez-Guerrero SA, Lozano-Zavaleta V, Selva-Pallares JE, Hernádez-Rodríguez JM, Cardiel-Silva M, Castillo-Rivera MH, Villela L, Loarca-Piña LM, Zurita-Martínez H, Graham-Casassus J, Azaola-Espinosa P, Silva-López S, Armenta-San Sebastián JA, Mijangos-Huesca F, Pérez-Osorio JE, Aldaco-Sarvide F, Castellanos G, Ramírez-Ibarguen AF, Zapata-Canto N, Labardini-Méndez JR. [National guidelines of diagnosis and treatment of the non-Hodgkin lymphoma]. Rev Invest Clin 2013; 65 Suppl 2:s5-s27. [PMID: 24459777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Non-Hodgkin lymphoma comprises a heterogeneous group of haematological malignancies, classified according to their clinic, anatomic-pathological features and, lately, to their molecular biomarkers. Despite the therapeutic advances, nearly half of the patients will die because of this disease. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine. In the face of poor diagnoses devices in most of the Mexican hospitals, we recommend the present diagnose stratification, and treatment guidelines for non-Hodgkin lymphoma, based on evidence. They include the latest and most innovative therapeutic approaches, as well as specific recommendations for hospitals with limited framework and therapy resources.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Ramón Rivas-Llamas
- Departamento de Hematologia, Banco de Sangre y Unidad de Aféresis Hospital General de Culiacán SSA, Culiacin, Sinaloa
| | - Jorge Luis Aquino-Salgado
- Departamento de Hematologia, Banco de Sangre y Unidad de Aféresis Hospital General de Culiacán SSA, Culiacin, Sinaloa
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Mariela Cardiel-Silva
- Centenario Hospital Miguel Hidalgo, ISSSTE Hospital General Núm. 26 RAC, Aguascalientes
| | | | - Luis Villela
- Centro Médico Zambrano Hellion de Tec Salud, Teciológico de Monterrey, Monterrey, NL
| | | | | | | | | | | | | | | | | | - Fernando Aldaco-Sarvide
- Servicio de Oncología Médica del Centro Médico Nacional 20 de Noviembre, ISSSTE, México, D.F
| | - Guillermo Castellanos
- Anatomía Patológica-Citopatología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS
| | | | | | | |
Collapse
|
2
|
Agreda-Vásquez GP, Espinosa-Poblano I, Sánchez-Guerrero SA, Crespo-Solís E, Cabrera-Vásquez S, López-Salmorán J, Barajas J, Peñaloza-Ramírez P, Tirado-Cárdenas N, Velázquez A. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective. J Clin Apher 2009; 23:163-7. [PMID: 18819155 DOI: 10.1002/jca.20175] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
UNLABELLED Therapeutic plasma exchange (TPE) is an effective treatment in Myasthenia gravis (MG) and Guillain-Barré syndrome (GBS) and 5% human albumin is the replacement fluid of choice; however, it is expensive. More recently, it has been suggested that starch is a safe and cheaper choice to human albumin. OBJECTIVE To evaluate our 5-year experience using 3% hydroxyethyl starch (HES) and 5% human albumin mixture, as replacement fluid in TPE for these diseases. MATERIALS AND METHODS Retrospective study carried out from January 2001 through September 2006. We included those patients with MG and GBS undergoing TPE. We analyzed clinical outcome (CO) and adverse events (AE) and our results were compared with a previous study which included similar patients undergoing TPE using just 5% human albumin. RESULTS Thirty-one procedures were carried out in 26 patients, a total of 147 TPE sessions. In the group of MG we had 57% complete responses (CR) and 86% overall response (OR) while in the group of GBS we had 40% CR and 60% OR. When we analyzed our CO with the previous study no statistical differences were found. Mean processed plasma volume (PPV) was 4.2 in MG and 5.5 in GBS. Twenty patients had AE, being hypotension and catheter dysfunction the most frequent ones, while tachycardia, hypertension and paresthesias were statistically more frequent in the HES/albumin group. CONCLUSIONS TPE with a mixture of 3% HES and 5% human albumin is as effective and safe as 5% human albumin alone for patients with these diseases.
Collapse
Affiliation(s)
- Gladys P Agreda-Vásquez
- Department of Hematology-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, México.
| | | | | | | | | | | | | | | | | | | |
Collapse
|